Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Diabetes Investigation"
DOI: 10.1111/jdi.14000
Abstract: Few studies have examined the effects of glucagon‐like peptide‐1 receptor agonist switching, particularly in Japanese patients. Therefore, we aimed to investigate the effects of switching from liraglutide to semaglutide or dulaglutide on blood glucose, body… read more here.
Keywords: liraglutide semaglutide; switching liraglutide; dulaglutide patients; effects switching ... See more keywords
Comparison of the Effectiveness of Liraglutide vs Semaglutide in a Veteran Population.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of pharmacy practice"
DOI: 10.1177/08971900221087127
Abstract: BACKGROUND Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are commonly prescribed medications for patients with type 2 diabetes mellitus (T2DM) based on cardiovascular benefits. OBJECTIVE This study aimed to evaluate efficacy and tolerability of once daily… read more here.
Keywords: comparison effectiveness; veteran population; effectiveness liraglutide; liraglutide semaglutide ... See more keywords
Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review
Sign Up to like & getrecommendations! Published in 2022 at "Therapeutic Advances in Chronic Disease"
DOI: 10.1177/20406223221108064
Abstract: Background & Objective: Although data on the effects of liraglutide and semaglutide in patients with diabetes have been reviewed, their therapeutic outcomes in obese/overweight individuals without diabetes have not been summarized. We conducted a systematic… read more here.
Keywords: liraglutide semaglutide; without diabetes; control groups; systematic review ... See more keywords
641-P: Novel Microsphere Formulation Developments of Long-Acting GLP-1 RA Including Exenatide, Liraglutide, and Semaglutide
Sign Up to like & getrecommendations! Published in 2021 at "Diabetes"
DOI: 10.2337/db21-641-p
Abstract: Objective: Clinical applications of Glucagon-like peptide-1 receptor agonists (GLP1-RA) were greatly limited due to its short half-life. The current study aims at the formulation and characterization of sustained-release (SR)-GLP1-RAs to prolong the release profile with… read more here.
Keywords: lag phase; long acting; liraglutide semaglutide; formulation ... See more keywords